Swidan, Sahar Z. PharmD, BCPS
Clinical Pharmacy Specialist, Head and Chronic Pain Unit, Michigan Head Pain and Neurological Institute and Chelsea Community Hospital; and Adjunct Associate Professor of Pharmacy, University of Michigan, Ann Arbor, MI
Dr. Swidan has disclosed that she is a consultant for and a member of the speakers bureaus of Merck & Co., GlaxoSmithKline, Eli Lilly, and Johnson & Johnson.
The author also has disclosed that the use of duloxetine for the treatment of chronic pain conditions such as fibromyalgia and for stress incontinence as discussed in this article has not been approved by the U.S. Food and Drug Administration.
Wolters Kluwer Health has identified and resolved all faculty conflicts of interest regarding this educational activity.
